O	0	9	Increased
O	10	14	risk
O	15	17	of
O	18	28	recurrence
O	29	34	after
B-intervention	35	42	hormone
I-intervention	43	54	replacement
I-intervention	55	62	therapy
O	63	65	in
O	66	72	breast
O	73	79	cancer
O	80	89	survivors
O	89	90	.

O	91	98	Hormone
O	99	110	replacement
O	111	118	therapy
O	119	120	(
O	120	122	HT
O	122	123	)
O	124	126	is
O	127	132	known
O	133	135	to
O	136	144	increase
O	145	148	the
O	149	153	risk
O	154	156	of
O	157	163	breast
O	164	170	cancer
O	171	173	in
O	174	181	healthy
O	182	187	women
O	187	188	,
O	189	192	but
O	193	196	its
O	197	203	effect
O	204	206	on
O	207	213	breast
O	214	220	cancer
O	221	225	risk
O	226	228	in
O	229	235	breast
O	236	242	cancer
O	243	252	survivors
O	253	255	is
O	256	260	less
O	261	266	clear
O	266	267	.

O	268	271	The
O	272	282	randomized
O	283	289	HABITS
O	290	295	study
O	295	296	,
O	297	302	which
O	303	311	compared
O	312	314	HT
O	315	318	for
O	319	329	menopausal
O	330	338	symptoms
O	339	343	with
O	344	348	best
O	349	359	management
O	360	367	without
O	368	376	hormones
O	377	382	among
B-eligibility	383	388	women
I-eligibility	389	393	with
I-eligibility	394	404	previously
I-eligibility	405	412	treated
I-eligibility	413	419	breast
I-eligibility	420	426	cancer
O	426	427	,
O	428	431	was
O	432	439	stopped
O	440	445	early
O	446	449	due
O	450	452	to
O	453	463	suspicions
O	464	466	of
O	467	469	an
O	470	479	increased
O	480	484	risk
O	485	487	of
O	488	491	new
O	492	498	breast
O	499	505	cancer
O	506	512	events
O	513	522	following
O	523	525	HT
O	525	526	.

O	527	529	We
O	530	537	present
O	538	545	results
O	546	551	after
O	552	560	extended
O	561	567	follow
O	567	568	-
O	568	570	up
O	570	571	.

O	572	578	HABITS
O	579	582	was
O	583	584	a
O	585	595	randomized
O	595	596	,
O	597	600	non
O	600	601	-
O	601	608	placebo
O	608	609	-
O	609	619	controlled
O	620	634	noninferiority
O	635	640	trial
O	641	645	that
O	646	651	aimed
O	652	654	to
O	655	657	be
O	658	660	at
O	661	662	a
O	663	668	power
O	669	671	of
O	672	674	80
O	674	675	%
O	676	678	to
O	679	685	detect
O	686	687	a
O	688	690	36
O	690	691	%
O	692	700	increase
O	701	703	in
O	704	707	the
O	708	714	hazard
O	715	720	ratio
O	721	722	(
O	722	724	HR
O	724	725	)
O	726	729	for
O	730	731	a
O	732	735	new
O	736	742	breast
O	743	749	cancer
O	750	755	event
O	756	765	following
O	766	768	HT
O	768	769	.

O	770	773	Cox
O	774	780	models
O	781	785	were
O	786	790	used
O	791	793	to
O	794	802	estimate
O	803	811	relative
O	812	817	risks
O	818	820	of
O	821	822	a
O	823	829	breast
O	830	836	cancer
O	837	842	event
O	842	843	,
O	844	847	the
O	848	855	maximum
O	856	866	likelihood
O	867	873	method
O	874	877	was
O	878	882	used
O	883	885	to
O	886	895	calculate
O	896	898	95
O	898	899	%
O	900	910	confidence
O	911	920	intervals
O	921	922	(
O	922	925	CIs
O	925	926	)
O	926	927	,
O	928	931	and
O	932	935	chi
O	935	936	(
O	936	937	2
O	937	938	)
O	939	944	tests
O	945	949	were
O	950	954	used
O	955	957	to
O	958	964	assess
O	965	976	statistical
O	977	989	significance
O	989	990	,
O	991	995	with
O	996	999	all
O	1000	1001	P
O	1002	1008	values
O	1009	1014	based
O	1015	1017	on
O	1018	1021	two
O	1021	1022	-
O	1022	1027	sided
O	1028	1033	tests
O	1033	1034	.

O	1035	1038	The
O	1039	1047	absolute
O	1048	1052	risk
O	1053	1055	of
O	1056	1057	a
O	1058	1061	new
O	1062	1068	breast
O	1069	1075	cancer
O	1076	1081	event
O	1082	1085	was
O	1086	1095	estimated
O	1096	1100	with
O	1101	1104	the
O	1105	1115	cumulative
O	1116	1125	incidence
O	1126	1134	function
O	1134	1135	.

O	1136	1140	Most
O	1141	1149	patients
O	1150	1153	who
O	1154	1162	received
O	1163	1165	HT
O	1166	1170	were
O	1171	1181	prescribed
O	1182	1192	continuous
O	1193	1201	combined
O	1202	1204	or
O	1205	1215	sequential
O	1216	1225	estradiol
O	1226	1237	hemihydrate
O	1238	1241	and
O	1242	1256	norethisterone
O	1256	1257	.

O	1258	1260	Of
O	1261	1264	the
B-total-participants	1265	1268	447
O	1269	1274	women
O	1275	1283	randomly
O	1284	1292	assigned
O	1292	1293	,
B-total-participants	1294	1297	442
O	1298	1303	could
O	1304	1306	be
O	1307	1315	followed
O	1316	1319	for
O	1320	1321	a
O	1322	1328	median
O	1329	1331	of
O	1332	1333	4
O	1334	1339	years
O	1339	1340	.

B-iv-bin-abs	1341	1347	Thirty
I-iv-bin-abs	1347	1348	-
I-iv-bin-abs	1348	1352	nine
O	1353	1355	of
O	1356	1359	the
B-intervention-participants	1360	1363	221
O	1364	1369	women
O	1370	1372	in
O	1373	1376	the
O	1377	1379	HT
O	1380	1383	arm
O	1384	1387	and
B-cv-bin-abs	1388	1390	17
O	1391	1393	of
O	1394	1397	the
B-control-participants	1398	1401	221
O	1402	1407	women
O	1408	1410	in
O	1411	1414	the
B-control	1415	1422	control
I-control	1423	1426	arm
O	1427	1438	experienced
O	1439	1440	a
B-outcome	1441	1444	new
I-outcome	1445	1451	breast
I-outcome	1452	1458	cancer
I-outcome	1459	1464	event
O	1465	1466	(
O	1466	1468	HR
O	1469	1470	=
O	1471	1472	2
O	1472	1473	.
O	1473	1474	4
O	1474	1475	,
O	1476	1478	95
O	1478	1479	%
O	1480	1482	CI
O	1483	1484	=
O	1485	1486	1
O	1486	1487	.
O	1487	1488	3
O	1489	1491	to
O	1492	1493	4
O	1493	1494	.
O	1494	1495	2
O	1495	1496	)
O	1496	1497	.

B-outcome	1498	1508	Cumulative
I-outcome	1509	1519	incidences
I-outcome	1520	1522	at
I-outcome	1523	1524	5
I-outcome	1525	1530	years
O	1531	1535	were
B-iv-bin-percent	1536	1538	22
I-iv-bin-percent	1538	1539	.
I-iv-bin-percent	1539	1540	2
I-iv-bin-percent	1540	1541	%
O	1542	1544	in
O	1545	1548	the
O	1549	1551	HT
O	1552	1555	arm
O	1556	1559	and
B-cv-bin-percent	1560	1561	8
I-cv-bin-percent	1561	1562	.
I-cv-bin-percent	1562	1563	0
I-cv-bin-percent	1563	1564	%
O	1565	1567	in
O	1568	1571	the
O	1572	1579	control
O	1580	1583	arm
O	1583	1584	.

O	1585	1587	By
O	1588	1591	the
O	1592	1595	end
O	1596	1598	of
O	1599	1605	follow
O	1605	1606	-
O	1606	1608	up
O	1608	1609	,
B-iv-bin-abs	1610	1613	six
O	1614	1619	women
O	1620	1622	in
O	1623	1626	the
O	1627	1629	HT
O	1630	1633	arm
O	1634	1637	had
B-outcome	1638	1642	died
I-outcome	1643	1645	of
I-outcome	1646	1652	breast
I-outcome	1653	1659	cancer
O	1660	1663	and
B-iv-bin-abs	1664	1667	six
O	1668	1672	were
O	1673	1678	alive
O	1679	1683	with
B-outcome	1684	1691	distant
I-outcome	1692	1702	metastases
O	1702	1703	.

O	1704	1706	In
O	1707	1710	the
O	1711	1718	control
O	1719	1722	arm
O	1722	1723	,
B-cv-bin-abs	1724	1728	five
O	1729	1734	women
O	1735	1738	had
B-outcome	1739	1743	died
I-outcome	1744	1746	of
I-outcome	1747	1753	breast
I-outcome	1754	1760	cancer
O	1761	1764	and
B-cv-bin-abs	1765	1769	four
O	1770	1773	had
B-outcome	1774	1784	metastatic
I-outcome	1785	1791	breast
I-outcome	1792	1798	cancer
O	1799	1800	(
O	1800	1801	P
O	1802	1803	=
O	1804	1805	.
O	1805	1807	51
O	1807	1808	,
O	1809	1812	log
O	1812	1813	-
O	1813	1817	rank
O	1818	1822	test
O	1822	1823	)
O	1823	1824	.

O	1825	1830	After
O	1831	1839	extended
O	1840	1846	follow
O	1846	1847	-
O	1847	1849	up
O	1849	1850	,
O	1851	1856	there
O	1857	1860	was
O	1861	1862	a
O	1863	1873	clinically
O	1874	1877	and
O	1878	1891	statistically
O	1892	1903	significant
O	1904	1913	increased
O	1914	1918	risk
O	1919	1921	of
O	1922	1923	a
O	1924	1927	new
O	1928	1934	breast
O	1935	1941	cancer
O	1942	1947	event
O	1948	1950	in
O	1951	1960	survivors
O	1961	1964	who
O	1965	1969	took
O	1970	1972	HT
O	1972	1973	.
